Koji Hasegawa

Koji Hasegawa

Director, Division of Translational Research

FACC FAHA MD PhD

National Hospital Organization Kyoto Medical Center, Fushimi-ku, Kyoto, JP

  • Radcliffe
  • OrcidID

Research areas

Obesity

Biography

Director, Division of Translational Research, Kyoto Medical Center
Leader, Cardiovascular Clinical Research Network, National Hospital Organization
Visiting Professor, University of Shizuoka
Past President, International Society of Cardiovascular Pharmacotherapy (2018)

Dr Koji Hasegawa is on the Editorial Board of European Cardiology Review.

 

Read more

Media

Management of Acute Heart Failure: Improvement of Hemodynamics With Appropriate Decongestion

Jack Tan Wei Chieh, Koji Hasegawa, Jin Joo Park, et al

Watch time: 1h 20m 49s
Image

Koji Hasegawa, Masayuki Yoshida

Watch time: 28m 50s

Articles by Koji Hasegawa, Director, Division of Translational Research

What is the Future Position of Factor XIa Inhibitors for Patients with Atrial Fibrillation?

Maki Komiyama, Moritake Iguchi, Hiromichi Wada, et al

Published:

Citation: European Cardiology Review 2024;19:e10.

DOI:

https://doi.org/10.15420/ecr.2023.50
When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention

Moritake Iguchi, Hiromichi Wada, Felipe Martínez, et al

Published:

Citation: European Cardiology Review 2023;18:e41.

DOI:

https://doi.org/10.15420/ecr.2022.62
Randomised Double-blind Placebo-Controlled Multicentre Trial for the Effects of Yokukansan in Smokers with Depressive Tendencies

Maki Komiyama, Yuka Ozaki, Hiromichi Wada, et al

Published:

Citation: European Cardiology Review 2023;18:e30.

DOI:

https://doi.org/10.15420/ecr.2023.18.PO13
Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients

Maki Komiyama, Gheorghe-Andrei Dan, Koji Hasegawa, et al

Published:

Citation: European Cardiology Review 2023;18:e14.

DOI:

https://doi.org/10.15420/ecr.2022.66
European Society of Cardiology Highlights: Late-breaking Trials – COVID-19

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2022;17:e04.

DOI:

https://doi.org/10.15420/ecr.2022.03
The Natural Product Zerumbone Suppresses Pressure Overload-Induced Cardiac Dysfunction by Inhibiting Cardiac Hypertrophy and Fibrosis

Mikuto Tojima, Yasufumi Katanasaka, Yoichi Sunagawa, et al

Published:

Citation: European Cardiology Review 2021;16:e70.

DOI:

https://doi.org/10.15420/ecr.2021.16.PO14
A Novel Curcumin Formulation, ASD-Cur, Suppressed the Development of Systolic Dysfunction After Myocardial Infarction in Rats

Hidemichi Takai, Yoichi Sunagawa, Masafumi Funamoto, et al

Published:

Citation: European Cardiology Review 2021;16:e69.

DOI:

https://doi.org/10.15420/ecr.2021.16.PO13
The Polyunsaturated Fatty Acids EPA and DHA Prevent Myocardial Infarction-induced Heart Failure by Inhibiting p300-HAT Activity in Rats

Yoichi Sunagawa, Ayumi Katayama, Masafumi Funamoto, et al

Published:

Citation: European Cardiology Review 2021;16:e68.

DOI:

https://doi.org/10.15420/ecr.2021.16.PO12
Discovery of Novel Small Molecules for Heart Failure Therapy Using Cultured Cardiomyocyte by High Throughput Screening Assay

Satoshi Shimizu, Miho Yamada, Takahiro Katagiri, et al

Published:

Citation: European Cardiology Review 2021;16:e66.

DOI:

https://doi.org/10.15420/ecr.2021.16.PO10
Chrysanthemum morifolium Extract Prevents the Development of Doxorubicin-induced Heart Failure

Masaya Ono, Yoichi Sunagawa, Yasufumi Katanasaka, et al

Published:

Citation: European Cardiology Review 2021;16:e65.

DOI:

https://doi.org/10.15420/ecr.2021.16.PO9
The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes

Tomoaki Ishida, Tomoe Ueyama, Ai Baba, et al

Published:

Citation: European Cardiology Review 2021;16:e64.

DOI:

https://doi.org/10.15420/ecr.2021.16.PO8
β3 Adrenergic Receptors in the Sinoatrial Node for Heart Rate Regulation

Shu Nakao, Kazuki Yanagisawa, Tomoe Ueyama, et al

Published:

Citation: European Cardiology Review 2021;16:e58.

DOI:

https://doi.org/10.15420/ecr.2021.16.PO2
Compound A, a Ginger Extract, Significantly Reduces Pressure Overload-induced Systolic Heart Failure in Mice

Yuto Kawase, Kana Shimizu, Masafumi Funamoto, et al

Published:

Citation: European Cardiology Review 2021;16:e57.

DOI:

https://doi.org/10.15420/ecr.2021.16.PO1
Coronavirus Disease 2019: Psychological Stress and Cardiovascular Diseases

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2021;16:e33.

DOI:

https://doi.org/10.15420/ecr.2021.10
Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management

Daniel TT Chong, Felicita Andreotti, Peter Verhamme, et al

Published:

Citation: European Cardiology Review 2021;16:e23.

DOI:

https://doi.org/10.15420/ecr.2020.43
Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e58.

DOI:

https://doi.org/10.15420/ecr.2020.24
Response to the Comment ‘Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019’

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e55.

DOI:

https://doi.org/10.15420/ecr.2020.25
Dilated Cardiomyopathy Risk in Patients with Coronavirus Disease 2019: How to Identify and Characterise it Early?

Maki Komiyama, Koji Hasegawa, Akira Matsumori, et al

Published:

Citation: European Cardiology Review 2020;15:e49.

DOI:

https://doi.org/10.15420/ecr.2020.17
A Multicentre, Open-Label, Randomised Controlled Clinical Trial to Assess the Efficacy and Safety of Appropriate Target Values for Lipid Management in Patients who Have Mild to Moderate Stenotic Lesions with High-Risk Plaques in Coronary Arteries

Morihiro Matsuda, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e47.

DOI:

https://doi.org/10.15420/ecr.2020.15.1.PO24
Applications for Induced Pluripotent Stem Cells in Disease Modelling and Drug Development for Heart Diseases

Shu Nakao, Dai Ihara, Koji Hasegawa, et al

Published:

Citation: European Cardiology Review 2020;15:e02.

DOI:

https://doi.org/10.15420/ecr.2019.03
Smoking Cessation as a Public Health Measure to Limit the Coronavirus Disease 2019 Pandemic

Maki Komiyama, Koji Hasegawa,

Published:

Citation: European Cardiology Review 2020;15:e16.

DOI:

https://doi.org/10.15420/ecr.2020.11
Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases

Kana Shimizu, Masafumi Funamoto, Yoichi Sunagawa, et al

Published:

Citation: European Cardiology Review 2019;14(2):117–22

DOI:

https://doi.org/10.15420/ecr.2019.17.2
Obesity and Cardiovascular Risk After Quitting Smoking: The Latest Evidence

Koji Hasegawa, Maki Komiyama, Yuko Takahashi, et al

Published:

Citation: European Cardiology Review 2019;14(1):60–1

DOI:

https://doi.org/10.15420/ecr.2019.4.2
23rd Annual Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy

Koji Hasegawa,

Citation: European Cardiology Review 2018;13(2):119

DOI:

https://doi.org/10.15420/ecr.2018.13.2.GE2
Erratum to: The Inhibitory Effects of Crucumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine- Induced Responses in Cardiomyocytes

Mai Genpei, Yoichi Sunagawa, Masafumi Funamoto, et al

Citation: European Cardiology Review 2018;13(2):136.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.ER1
Analysis of the Effects of EPA and DHA on Cardiomyocyte hypertrophy

Ayumi Katayama, Masafumi Funamoto, Kana Shimizu, et al

Citation: European Cardiology Review 2018;13(2):121.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO2
Relationship Between VEGF-C Levels and Mortality in Patients with Peripheral Artery Disease

Nobutoyo Masunaga, Shuichi Ura, Mitsuru Ishii, et al

Citation: European Cardiology Review 2018;13(2):123.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO4
VEGF-C and Cardiovascular Mortality in Patients Undergoing Drug-eluting Stent Implantation

Takashi Unoki, Shuichi Ura, Daisuke Takagi, et al

Citation: European Cardiology Review 2018;13(2):124.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO5
The GATA4 Acetylation Site Plays a Key Role in the Development of Cardiomyocyte Hypertrophy

Satoshi Shimizu, Yoichi Sunagawa, Kodai Hara, et al

Citation: European Cardiology Review 2018;13(2):125.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO6
TBL1 Suppresses Cardiomyocyte Hypertrophy by Regulating the Interaction Between HDAC3 and GATA4

Yasufumi Katanasaka, Masatoshi Namiki, Yoichi Sunagawa, et al

Citation: European Cardiology Review 2018;13(2):126.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO7
Relationship Between VEGF-C Levels and All-cause Mortality in Patients with Chronic Heart Failure

Moritake Iguchi, Shuichi Ura, Nobutoyo Masunaga, et al

Citation: European Cardiology Review 2018;13(2):129.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO10
A PRMT5 Selective Inhibitor EPZ015666 Suppressed TAC-induced Left Ventricular Dysfunction

Kazuma Hanajima, Yusuke Miyazaki, Yasufumi Katanasaka, et al

Citation: European Cardiology Review 2018;13(2):130.

DOI:

https://doi.org/10.15420/ecr.2018.13.2.PO11
ISCP Guest Editorial: Cardiovascular Disease Prevention in Diabetes

Maki Komiyama, Koji Hasegawa,

Citation: European Cardiology Review 2018;13(1):21–2.

DOI:

https://doi.org/10.15420/ecr.13.1.1.GE1
Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy

Koji Hasegawa,

Citation: European Cardiology Review 2017;12(2):88

DOI:

https://doi.org/10.15420/ecr.2017:25:1
Analysis of Factors Associated with Smoking Relapse

Sayaka Shimada, Maki Komiyama, Hiromichi Wada, et al

Citation: European Cardiology Review 2017;12(2):111.

DOI:

https://doi.org/10.15420/ecr.2017:23:20
A Transcriptional Co-activator, p300 is Involved in the Epigenetic Gene Activation on Hypertrophic Response Gene Promoters in Heart Failure

Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, et al

Citation: European Cardiology Review 2017;12(2):110.

DOI:

https://doi.org/10.15420/ecr.2017:23:19
The Inhibitory Effects of Curcumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes

Mai Genpei, Yoichi Sunagawa, Masafumi Funamoto, et al

Citation: European Cardiology Review 2017;12(2):107.

DOI:

https://doi.org/10.15420/ecr.2017:23:16
Curcumin Analogue GO-Y030 Significantly Improves Pressure Overload-induced Heart Failure in Vivo

Kana Shimizu, Masafumi Funamoto, Mai Genpei, et al

Citation: European Cardiology Review 2017;12(2):106.

DOI:

https://doi.org/10.15420/ecr.2017:23:15
A Novel Target Molecule of Nobiletin Derived from Citrus Peels has a Therapeutic Potency Against the Development of Heart Failure

Yoichi Sunagawa, Masafumi Funamoto, Anna Suzuki, et al

Citation: European Cardiology Review 2017;12(2):105.

DOI:

https://doi.org/10.15420/ecr.2017:23:14
Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

Maki Komiyama, Hiromichi Wada, Hajime Yamakage, et al

Citation: European Cardiology Review 2017;12(2):96.

DOI:

https://doi.org/10.15420/ecr.2017:23:5
Nobiletin a Citrus Flavonoid, Exerts Additional Effects with Angiotensin II Receptor Blocker on Systolic Function in Salt-sensitive Dahl Rats

Haruka Ebi, Masafumi Funamoto, Yoichi Sunagawa, et al

Citation: European Cardiology Review 2017;12(2):92.

DOI:

https://doi.org/10.15420/ecr.2017:23:1